Marker Therapeutics Inc. Stock News

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t

HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th

Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer signif

Marker Therapeutics (NASDAQ: MRKR ) stock is rising higher on Wednesday as investors react to positive pre-clinical news from the clinical-stage immuno-oncology company. Today's results come from a te

More low float penny stocks to watch. The post 7 Low Float Penny Stocks To Watch After SNTG Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022.

If you're watching the action in the stock market today, you're seeing plenty of chop. The U.S. dollar's strength has pushed broader markets lower, but a mix of positive and negative economic against

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunoth

Marker Therapeutics Inc (NASDAQ: MRKR ) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1 . The company reported initial results from the Phase 2 trial for MT-401 as a treatment option for Acute myeloid leukemia (AML) in the post-transplant setting. No dose-limiting toxicities, cytokine release syndrome, or neurotoxicity were observed. 1 MRD+ patient became MRD- after infusion … Full story available on Benzinga.com

Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1. The company reported initial

The

Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for pancreatic cancer. Following

Marker Therapeutics Inc (MRKR) shares closed today at 1.4% above its 52 week low of $0.84, giving the company a market cap of $71M. The stock is currently down 10.0% year-to-date, down 52.2% over the past 12 months, and down 80.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 16.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Communication Services industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 529.8% The company's stock price performance over the past 12 months lags the peer average by 69.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Marker Therapeutics Inc (MRKR) shares closed today at 1.9% above its 52 week low of $0.98, giving the company a market cap of $82M. The stock is currently down 31.1% year-to-date, down 34.7% over the past 12 months, and down 78.5% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 45.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Communication Services industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8.6% The company's stock price performance over the past 12 months lags the peer average by 14.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.